A Phase 3, Multicenter, Randomized, Open-Label Study of Avelumab (MSB0010718C) Alone or in Combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin Alone In Patients with Platinum-Resistant/Refractory Ovarian Cancer
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Avelumab (Primary) ; Doxorubicin liposomal
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN OVARIAN 200
- Sponsors Pfizer
Most Recent Events
- 03 Oct 2023 Results analyzing cardiac adverse events , published in the Oncologist
- 27 Jul 2022 This trial has been completed in France (Date of the global end of the trial : 12-Jul-2022), according to European Clinical Trials Database record.
- 25 Jul 2022 Status changed from active, no longer recruiting to completed.